All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Exploration of ADCs Highlights the Drive for Personalized Treatment in Ovarian Cancer

October 26th 2022

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

Camizestrant Improves PFS Vs Fulvestrant in Advanced ER+ Breast Cancer

October 26th 2022

Camizestrant led to a statistically significant improvement in progression-free survival compared with fulvestrant in postmenopausal patients with estrogen receptor–positive, locally advanced, or metastatic breast cancer who were previously treated with endocrine therapy for advanced disease.

Early Data Underscore the Potential of Neoadjuvant Immunotherapy in Advanced Resectable CSCC

October 26th 2022

Neil D. Gross, MD, FACS, discusses the current deficits in the treatment of patients with cutaneous squamous cell carcinoma in the curative setting and avenues for continued research generated by the primary analysis of the phase 2 trial examining neoadjuvant cemiplimab in this population.

Chemoimmunotherapy Combo Elicits Encouraging Responses in Relapsed High-Risk Neuroblastoma

October 25th 2022

The 4-drug combination of irinotecan, temozolomide, dinutuximab, and granulocyte-macrophage colony-stimulating factor elicited objective responses in almost half of patients with high-risk neuroblastoma.

FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

October 25th 2022

The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Neoadjuvant Therapy and Surgical Advances Continue to Shift Treatment Options for Breast Cancer

October 25th 2022

Jeannie Shen, MD, discussed the shifts in surgical practice for patients with breast cancer, the need for a multidisciplinary approach to optimize treatment for individual patients, and ongoing efforts at Huntington Hospital and Cedars-Sinai to increase awareness and improve care for these patients.

Sintilimab Plus Chemotherapy Improves PFS in Pretreated, EGFR-Mutant NSCLC

October 25th 2022

Sintilimab plus pemetrexed and cisplatin significantly improved progression-free survival vs pemetrexed and cisplatin alone in patients with advanced, EGFR-mutant non–small cell lung cancer who progressed on prior EGFR TKI therapy.

Dr. Terry Hyslop Joins SKCC as Cancer Risk and Control Program Co-leader and Center for Health Equity Director

October 25th 2022

Jefferson Health’s Sidney Kimmel Cancer Center welcomes transdisciplinary population health researcher Terry Hyslop, PhD, as Co-leader of the Cancer Risk and Control Program.

Investigators Seek to Refocus on FGFR2-altered Cholangiocarcinoma

October 25th 2022

Investigators hope to add RLY-4008, the first highly selective FGFR2 inhibitor, to the growing arsenal of treatment options for patients with cholangiocarcinoma.

Adjuvant Capecitabine Following Concurrent CRT Improves Failure-Free Survival in High-Risk Locally Advanced Nasopharyngeal Carcinoma

October 25th 2022

Treatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with locally advanced nasopharyngeal carcinoma carrying at least 2 high risk factors.

Cemiplimab Monotherapy Continues to Generate Responses in Locally Advanced or Metastatic CSCC

October 25th 2022

Single-agent cemiplimab demonstrated safety and efficacy in patients with locally advanced or metastatic cutaneous squamous cell carcinoma who comprised group 6 of the phase 2 EMPOWER-CSCC-1 trial that was in line with what was previously reported in groups 1, 2, and 3 of the study.

Immunotherapy-Based Endeavors Could Alter Treatment Landscape in Metastatic TNBC

October 24th 2022

Yuan Yuan, MD, PhD, discusses the role immune checkpoint inhibitors have played in the treatment of triple-negative breast cancer, ongoing efforts to investigate the role of immunotherapy in breast cancer, and the work Cedars-Sinai is conducting to promote breast cancer awareness.

Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme

October 24th 2022

Bevacizumab along with reirradiation extended progression-free survival compared with bevacizumab alone for patients with recurrent glioblastoma multiforme.

Real-World Data Could Help Inform Treatment Sequencing Decisions in HR+/HER2- Breast Cancer

October 24th 2022

Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.

Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer

October 24th 2022

The combination of cediranib and olaparib significantly improved radiographic progression-free survival compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer.

Merkel Cell Carcinoma Researcher Dr. Nick Salisbury named Brave Fellow

October 24th 2022

Rare skin cancer is focus of work by Fred Hutch scientist who will receive support honoring runner Gabe Grunewald.

FDA Grants Priority Review to Quizartinib for Newly Diagnosed FLT3-ITD–Positive AML

October 24th 2022

The FDA has accepted and granted priority review to the new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

Stark Differences in Mortality Rates Emphasize Ongoing Racial Disparities in Breast Cancer

October 24th 2022

Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.

FDA Approves Durvalumab/Tremelimumab in Unresectable HCC

October 24th 2022

The FDA has approved durvalumab (Imfinzi) in combination with tremelimumab (Imjudo) for the treatment of adult patients with unresectable hepatocellular carcinoma.

Xevinapant Plus Chemoradiotherapy Improves OS in Locally Advanced Head and Neck Cancer

October 22nd 2022

Xevinapant plus chemoradiotherapy more than halved the risk of death vs placebo plus chemoradiotherapy without increasing toxicity in patients with unresectable, locally advanced head and neck squamous cell carcinoma.